NCT04677933View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

December 22, 2020

Study Completion Date

December 22, 2020

Conditions
Osteoarthritis
Interventions
DRUG

A: OLP-1002

10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002

DRUG

B: OLP-1002

10 patients will receive 10 µg OLP-1002 BIW OLP-1002

DRUG

C: Placebo

10 patients will receive Placebo BIW

Trial Locations (4)

2148

Paratus Clinical Research Western Sydney, Blacktown

2289

Novatrials (Pendlebury Research), Newcastle

2617

Paratus Clinical Research- Canberra Trial Clinic, Canberra

3124

Emeritus Research, Camberwell

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

OliPass Australia Pty Ltd

INDUSTRY

NCT04677933 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002 | Biotech Hunter | Biotech Hunter